EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment of dyslipidemia: PCSK-9 in focus

Sandra Singh-Lukač, Ljiljana Popović, Iva Rasulić, Ana Petakov, Jelena Bogdanović, Marija Mitrović, Milica Krstić, Katarina Lalić

Medicinska istrazivanja · 2025

DOI: 10.5937/medi0-55356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicinska istrazivanja, 2025. Verfasst von Sandra Singh-Lukač und 7 weiteren Autor:innen. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disease is the leading cause of death worldwide, accounting for one-third of the total global mortality. Dyslipidemia is one of the most common risk factors and plays a cardinal role in the development and progression of atherosclerotic cardiovascular disease. Since statin therapy is often insufficient, or cardiovascular disease continues to develop despite achieving target lipid levels, current attention is focused on new therapeutic options with significantly greater efficacy. The reduction in LDL cholesterol levels with PCSK-9 inhibitors is about 60% when used as monotherapy and as much as 85% when combined with high-intensity statins and/or other lipid-lowering therapies. Alirocumab and evolocumab are two monoclonal antibodies that effectively bind to the LDL receptor, interfering with its degradation. Inclisiran is a small interfering RNA that interferes with the synthesis of PCSK-9 molecules and effectively reduces LDL-C. Indications for PCSK-9 inhibitors usage are increasingly expanding due to the discovery of their pleiotropic effects. Additionally, the focus is on discovering new mechanisms of PCSK-9 inhibition that would open the door to the development of new therapeutic agents. Studies on the efficacy and safety of oral PCSK9 inhibitors are ongoing, along with early-stage clinical trials exploring gene-editing strategies for the treatment of dyslipidemias. The purpose of this review article is to provide an overview of the current knowledge on the application of PCSK-9 inhibitors.

Zitieren

APA

Singh-Lukač, S., Popović, L., Rasulić, I., Petakov, A., Bogdanović, J., Mitrović, M., Krstić, M., & Lalić, K. (2025). Treatment of dyslipidemia: PCSK-9 in focus. Medicinska istrazivanja. https://doi.org/10.5937/medi0-55356

Vancouver

Singh-Lukač S, Popović L, Rasulić I, Petakov A, Bogdanović J, Mitrović M, et al. Treatment of dyslipidemia: PCSK-9 in focus. Medicinska istrazivanja. 2025. doi:10.5937/medi0-55356

BibTeX
@article{SinghLuka2025,
  author = {Singh-Lukač, Sandra and Popović, Ljiljana and Rasulić, Iva and Petakov, Ana and Bogdanović, Jelena and Mitrović, Marija and Krstić, Milica and Lalić, Katarina},
  title = {Treatment of dyslipidemia: PCSK-9 in focus},
  journal = {Medicinska istrazivanja},
  year = {2025},
  doi = {10.5937/medi0-55356}
}
Kostenlos starten →